首页> 外文OA文献 >PRM93 Validation of A Global Economic Model to Evaluate The Cost-Effectiveness Of Targeted Treatments Using Companion Diagnostics In Advanced/Metastatic Cancer Treatment Using Kras Testing For Cetuximab Therapy In Metastatic Colorectal Cancer

【2h】

PRM93 Validation of A Global Economic Model to Evaluate The Cost-Effectiveness Of Targeted Treatments Using Companion Diagnostics In Advanced/Metastatic Cancer Treatment Using Kras Testing For Cetuximab Therapy In Metastatic Colorectal Cancer

机译：PRM93验证了一种全球经济模型，以评估针对性疗法的成本-效果，该疗法在伴随/诊断转移性结直肠癌中使用克拉斯检验的西妥昔单抗疗法用于晚期/转移性癌症治疗中的伴随诊断

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Mathurin K.; Beauchemin C.; Lachaine J.;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No. 150 and part review of technology appraisal No. 118): a systematic review and economic model [J] . Health technology assessment: HTA . 2013,第14期

机译：一线化疗后西妥昔单抗（单药或联合化疗），贝伐单抗（与非奥沙利铂化疗联合）和帕尼单抗（单药）治疗转移性结直肠癌的临床疗效和成本效益（技术评估编号第150号技术评估和第118号技术评估的部分复审：系统复审和经济模型
2. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer [J] . HoyleM., PetersJ., CrathorneL., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2013,第2期

机译：西妥昔单抗，西妥昔单抗加伊立替康和帕尼单抗用于KRAS野生型转移性结直肠癌患者第三线及其他治疗的成本效益
3. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients [J] . European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：用伊立替康/西替昔单抗的治疗序列，然后进行Folfox-4或转移性结肠直肠癌患者的反向策略，在第一线Folfiri / Bevacizumab后进展：用于研究胃肠癌期III的意大利组，随机试验比较两种治疗序列结肠直肠转移性患者
4. PIK3CA Pathway and CTNNB1 Determine Poor Response of Cetuximab in Right-Sided Metastatic Colorectal Cancer [C] . Pi-Yueh Chang International Molecular Medicine Tri-Conference. . 2019

机译：Pik3CA途径和CTNNB1确定右侧转移性结肠直肠癌中西妥昔单抗的良差
5. New Models of Colorectal Cancer to Facilitate Therapy Development for Metastatic Disease [D] . O'Rourke, Kevin. 2017

机译：新型结肠直肠癌促进转移性疾病治疗的疗效
6. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy) bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. [O] . M Hoyle, L Crathorne, J Peters, -1

机译：一线化疗后西妥昔单抗（单药或联合化疗）贝伐单抗（与非奥沙利铂化疗联合）和帕尼单抗（单药）治疗转移性结直肠癌的临床疗效和成本效益（技术评估编号第150号技术评估书和第118号技术评估书的一部分复审：系统的复审和经济模型。
7. Development Of A Global Economic Model To Evaluate The Cost-Effectiveness Of Targeted Treatments Using Companion Diagnostics In Advanced/Metastatic Cancer Treatment [O] . K. Mathurin, C. Beauchemin, J. Lachaine 2014

机译：制定全球经济模式，以评估使用伴随癌症治疗伴治疗靶向治疗的成本效益

PRM93 Validation of A Global Economic Model to Evaluate The Cost-Effectiveness Of Targeted Treatments Using Companion Diagnostics In Advanced/Metastatic Cancer Treatment Using Kras Testing For Cetuximab Therapy In Metastatic Colorectal Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅